Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > ABBV AbbVie > Detailed Quotes

ABBV AbbVie

Watchlist
138.320
+4.110+3.06%
Close 10/03 16:00 ET
139.290
+0.97+0.70%
Pre Mkt Price 10/04 05:13 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
138.800
Open
135.880
Turnover
1.03B
Low
135.306
Pre Close
134.210
Volume
7.44M
Market Cap
244.56B
P/E(TTM)
19.56
52wk High
172.809
Shares
1.77B
P/E(Static)
21.44
52wk Low
103.748
Float Cap
243.93B
Bid/Ask %
-33.33%
Historical High
172.809
Shs Float
1.76B
Volume Ratio
0.99
Historical Low
21.807
Dividend TTM
5.42
Div Yield TTM
5.2
P/B
16.69
Dividend LFY
3.92%
Div Yield LFY
3.76%
Turnover Ratio
0.42%
Amplitude
2.60%
Avg Price
137.938
Lot Size
1
Float Cap
243.93B
Bid/Ask %
-33.33%
Historical High
172.809
Shs Float
1.76B
Volume Ratio
0.99
Historical Low
21.807
Dividend TTM
5.42
P/B
16.69
Dividend LFY
3.92%
Turnover Ratio
0.42%
Amplitude
2.60%
Avg Price
137.938
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson’s disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
CEO: Gonzalez, Richard A.
Market: NYSE
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top